Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - soft capsule - vinorelbine 20 mg - antineoplastic agents

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - soft capsule - vinorelbine 30 mg - antineoplastic agents

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - soft capsule - vinorelbine 80 mg - antineoplastic agents

Malta - English - Medicines Authority

medac gesellschaft fur klinische spezialpräparate mbh theaterstr. 6 22880 wedel, germany - soft capsule - vinorelbine 20 mg - antineoplastic agents

Malta - English - Medicines Authority

medac gesellschaft fur klinische spezialpräparate mbh theaterstr. 6 22880 wedel, germany - soft capsule - vinorelbine 30 mg - antineoplastic agents

Malta - English - Medicines Authority

medac gesellschaft fur klinische spezialpräparate mbh theaterstr. 6 22880 wedel, germany - soft capsule - vinorelbine 80 mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: polysorbate 80; titanium dioxide; iron oxide red; purified water; macrogol 400; partially dehydrated liquid sorbitol; gelatin - non-small cell lung cancer: vinorelbine lrx is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: vinorelbine lrx is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: gelatin; iron oxide red; partially dehydrated liquid sorbitol; titanium dioxide; macrogol 400; purified water; polysorbate 80 - non-small cell lung cancer: vinorelbine lu is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: vinorelbine lu is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: purified water; gelatin; polysorbate 80; macrogol 400; titanium dioxide; partially dehydrated liquid sorbitol; iron oxide yellow - non-small cell lung cancer: vinorelbine lrx is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: vinorelbine lrx is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: purified water; partially dehydrated liquid sorbitol; gelatin; macrogol 400; polysorbate 80; titanium dioxide; iron oxide yellow - non-small cell lung cancer: vinorelbine lu is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: vinorelbine lu is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.